Multitargeted anti-infective drugs: resilience to resistance in the antimicrobial resistance era.
Multitargeted anti-infective drugs: resilience to resistance in the antimicrobial resistance era.
复制标题
DOI：
10.4155/fdd-2022-0001
复制
发表时间：
2022-04
影响因子：
--
通讯作者：
Scott, Fraser J
中科院分区：
文献类型：
--
作者：
Suckling, Colin J;Hunter, Iain S;Scott, Fraser J
单分子-单一生物靶点-单一生物效应的标准药物发现范式可能特别不适合抗感染药物的发现。这是由于在单靶点药物中很可能观察到耐药性的快速演变。多靶点抗感染药物可能具有优势，因为它们对靶点相关耐药机制的易感性较低。Strathclyde minor groove binder是一类采用多靶点抗感染药物模式开发的化合物，本文讨论了其对多种病原生物的有效性。由于其可能的靶标包括DNA和RNA，因此将该类重命名为Strathclyde核酸结合物。
The standard drug discovery paradigm of single molecule – single biological target – single biological effect is perhaps particularly unsuitable for anti-infective drug discovery. This is due to the rapid evolution of resistance likely to be observed with single target drugs. Multitargeted anti-infective drugs are likely to be superior due to their lower susceptibility to target-related resistance mechanisms. Strathclyde minor groove binders are a class of compounds which have been developed by adopting the multitargeted anti-infective drugs paradigm, and their effectiveness against a wide range of pathogenic organisms is discussed. The renaming of this class to Strathclyde nucleic acid binders is also presented due to their likely targets including both DNA and RNA.